These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 28920661)

  • 21. PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine.
    Pilotto S; Peretti U; Novello S; Rossi G; Milella M; Giaj Levra M; Ciuffreda L; Massari F; Brunelli M; Tortora G; Bria E
    Expert Opin Pharmacother; 2013 Apr; 14(5):597-608. PubMed ID: 23472711
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prospective Study of Repeated Biopsy Feasibility and Acquired Resistance at Disease Progression in Patients With Advanced EGFR Mutant Lung Cancer Treated With Erlotinib in a Phase 2 Trial.
    Redig AJ; Costa DB; Taibi M; Boucher D; Johnson BE; Jänne PA; Jackman DM
    JAMA Oncol; 2016 Sep; 2(9):1240-2. PubMed ID: 27387964
    [No Abstract]   [Full Text] [Related]  

  • 23. Adjuvant Epidermal Growth Factor Receptor Inhibitors in Non-Small Cell Lung Cancer.
    Lourdes LS; Jalal SI; Hanna N
    Oncologist; 2015 Sep; 20(9):975-8. PubMed ID: 26268739
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pulse Dose Erlotinib and Zuckerguss Improvement in EGFR-Mutant NSCLC.
    Mehta P; Hamid O; Klempner SJ
    J Thorac Oncol; 2017 Dec; 12(12):1857-1858. PubMed ID: 28774860
    [No Abstract]   [Full Text] [Related]  

  • 25. Rapid response of brain metastasis to crizotinib in a patient with ALK rearrangement-positive non-small-cell lung cancer.
    Kaneda H; Okamoto I; Nakagawa K
    J Thorac Oncol; 2013 Apr; 8(4):e32-3. PubMed ID: 23486271
    [No Abstract]   [Full Text] [Related]  

  • 26. ALK-targeted therapy for lung cancer: ready for prime time.
    Husain H; Rudin CM
    Oncology (Williston Park); 2011 Jun; 25(7):597-601. PubMed ID: 21888258
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Successful crizotinib rechallenge after crizotinib-induced interstitial lung disease in patients with advanced non-small-cell lung cancer.
    Asai N; Yamaguchi E; Kubo A
    Clin Lung Cancer; 2014 May; 15(3):e33-5. PubMed ID: 24702855
    [No Abstract]   [Full Text] [Related]  

  • 28. Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations.
    Klughammer B; Brugger W; Cappuzzo F; Ciuleanu T; Mok T; Reck M; Tan EH; Delmar P; Klingelschmitt G; Yin AY; Spleiss O; Wu L; Shames DS
    J Thorac Oncol; 2016 Apr; 11(4):545-55. PubMed ID: 26773740
    [TBL] [Abstract][Full Text] [Related]  

  • 29. First-line crizotinib shows promise in patients with NSCLC.
    Bagcchi S
    Lancet Respir Med; 2015 Jan; 3(1):17. PubMed ID: 25497281
    [No Abstract]   [Full Text] [Related]  

  • 30. Novel molecular trends in the management of advanced non-small-cell lung cancer.
    Metro G; Crinò L
    Expert Rev Anticancer Ther; 2012 Jun; 12(6):729-32. PubMed ID: 22716489
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ALK-rearranged squamous cell lung carcinoma responding to crizotinib: A missing link in the field of non-small cell lung cancer?
    Vergne F; Quéré G; Andrieu-Key S; Descourt R; Quintin-Roué I; Talagas M; De Braekeleer M; Marcorelles P; Uguen A
    Lung Cancer; 2016 Jan; 91():67-9. PubMed ID: 26603857
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeted therapy for lung cancer.
    Petrosyan F; Daw H; Haddad A; Spiro T
    Anticancer Drugs; 2012 Nov; 23(10):1016-21. PubMed ID: 22932130
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Crizotinib in the management of advanced-stage non-small-cell lung cancer.
    Loong HH; Mok K; Leung LK; Mok TS
    Future Oncol; 2015; 11(5):735-45. PubMed ID: 25757678
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Mechanisms of resistance to crizotinib in patients with transforming EML4-ALK fusion gene].
    Zhang HJ; Zhang XT; Zhang L
    Zhonghua Bing Li Xue Za Zhi; 2012 Dec; 41(12):862-4. PubMed ID: 23324244
    [No Abstract]   [Full Text] [Related]  

  • 35. ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development.
    Scagliotti G; Stahel RA; Rosell R; Thatcher N; Soria JC
    Eur J Cancer; 2012 May; 48(7):961-73. PubMed ID: 22397764
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [ALK inhibitor].
    Sakamoto H
    Nihon Yakurigaku Zasshi; 2013 Jul; 142(1):48-50. PubMed ID: 23842228
    [No Abstract]   [Full Text] [Related]  

  • 37. [Current status and perspectives of individualized therapy for non-small cell lung cancer based on molecular targeting].
    Shi YK
    Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):398-400. PubMed ID: 22883466
    [No Abstract]   [Full Text] [Related]  

  • 38. The efficacy of crizotinib in patients with ALK-positive nonsmall cell lung cancer.
    Pender A; Popat S
    Ther Adv Respir Dis; 2015 Jun; 9(3):97-104. PubMed ID: 25801645
    [TBL] [Abstract][Full Text] [Related]  

  • 39. More than just an oncogene translocation and a kinase inhibitor: Kevin's story.
    Costa DB
    J Clin Oncol; 2012 Jan; 30(1):110-2. PubMed ID: 22067391
    [No Abstract]   [Full Text] [Related]  

  • 40. ROS1--targeting the one percent in lung cancer.
    Gold KA
    N Engl J Med; 2014 Nov; 371(21):2030-1. PubMed ID: 25409376
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.